title: Predicting the outcome of therapy for pulmonary tuberculosis.
abstract: Patients vary considerably in their response to treatment of pulmonary tuberculosis. Although several studies have indicated that adverse outcomes are more likely in those patients with delayed sputum sterilization, few tools are available to identify those patients prospectively. In this study, multivariate models were developed to predict the response to therapy in a prospectively recruited cohort of 42 HIV-uninfected subjects with drug-sensitive tuberculosis. The cohort included 2 subjects whose initial response was followed by drug-sensitive relapse. The total duration of culture positivity was best predicted by a model that included sputum M. tuberculosis antigen 85 concentration on Day 14 of therapy, days-to-positive in BACTEC on Day 30, and the baseline radiographic extent of disease (R = 0.63). A model in which quantitative AFB microscopy replaced BACTEC also performed adequately (R = 0.58). Both models predicted delayed clearance of bacilli in both relapses (> 85th percentile of all subjects) using information collected during the first month of therapy. Stratification of patients according to anticipated response to therapy may allow TB treatment to be individualized, potentially offering superior outcomes and greater efficiency in resource utilization, and aiding in the conduct of clinical trials.
authors.affiliation: Case Western Reserve University, Cleveland, Ohio 44106, USA. rsw2@po.cwru.edu
authors.forename: R S
authors.initials: RS
authors.lastname: Wallis
authors.forename: M D
authors.initials: MD
authors.lastname: Perkins
authors.forename: M
authors.initials: M
authors.lastname: Phillips
authors.forename: M
authors.initials: M
authors.lastname: Joloba
authors.forename: A
authors.initials: A
authors.lastname: Namale
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
authors.forename: C C
authors.initials: CC
authors.lastname: Whalen
authors.forename: L
authors.initials: L
authors.lastname: Teixeira
authors.forename: B
authors.initials: B
authors.lastname: Demchuk
authors.forename: R
authors.initials: R
authors.lastname: Dietze
authors.forename: R D
authors.initials: RD
authors.lastname: Mugerwa
authors.forename: K
authors.initials: K
authors.lastname: Eisenach
authors.forename: J J
authors.initials: JJ
authors.lastname: Ellner
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D001938:Brazil / Q000453:epidemiology; D015331:Cohort Studies; D003470:Culture Media; D006801:Humans; D016014:Linear Models; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000254:growth & development; D011446:Prospective Studies; D012008:Recurrence; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology; D014454:Uganda / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents; D003470:Culture Media